News | Proton Therapy | September 06, 2016

IBA and RaySearch Join Forces to Advance Adaptive Proton Therapy

Strategic alliance will work to integrate RaySearch’s RayCare oncology information system with IBA’s proton therapy delivery systems

IBA, RaySearch, adaptive proton therapy, RayCare oncology information system, strategic alliance

September 6, 2016 — IBA (Ion Beam Applications S.A.) and RaySearch Laboratories have entered into a long-term strategic alliance to combine their respective technologies and advance adaptive proton therapy.

As part of the collaboration, the RayCare oncology information system, which is currently in development at RaySearch, will be customized for optimal use together with the IBA delivery solutions. In both RayStation and RayCare, as well as in the IBA delivery solutions, joint features, dedicated software interfaces and modified graphical user interface components will allow for a close and seamless workflow integration with optimized performances. The result will be a complete turnkey solution for all software and hardware needed to deliver adaptive proton therapy treatment.

Proton therapy is one of the most precise forms of radiation therapy: Targets can be pinpointed with the optimal radiation dose, while adjacent tissue is spared to a much higher degree than with conventional radiation therapy. The technique is growing in popularity worldwide, and studies are converging to point towards the fact that approximately 20 percent of radiation therapy patients could benefit from proton therapy while only 1 percent receive it today.

For more information: www.raysearchlabs.com, www.iba-worldwide.com

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.